DrugPatentWatch Database Preview
Vorapaxar sulfate - Generic Drug Details
What are the generic sources for vorapaxar sulfate and what is the scope of patent protection?
Vorapaxar sulfate
is the generic ingredient in one branded drug marketed by Toprol and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Vorapaxar sulfate has one hundred and sixty-three patent family members in thirty-seven countries.
One supplier is listed for this compound.
Summary for vorapaxar sulfate
| International Patents: | 163 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 31 |
| Clinical Trials: | 1 |
| DailyMed Link: | vorapaxar sulfate at DailyMed |
Recent Clinical Trials for vorapaxar sulfate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme Corp. | Phase 2 |
| Matthew Mell | Phase 2 |
Pharmacology for vorapaxar sulfate
| Drug Class | Protease-activated Receptor-1 Antagonist |
| Mechanism of Action | Protease-activated Receptor-1 Antagonists |
Synonyms for vorapaxar sulfate
| 2-[(E)-2-{(3R,3aS,4S,4aR,7R,8aR,9aR)-7-[(ethoxycarbonyl)amino]-3-methyl-1-oxododecahydronaphtho[2,3-c]furan-4-yl}ethenyl]-5-(3-fluorophenyl)pyridinium hydrogen sulfate |
| 705260-08-8 |
| AKOS030524402 |
| AN-9455 |
| AS-35235 |
| Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(5-(3-fluorophenyl)-2-pyridinyl)ethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-c)furan-6-yl)-, ethyl ester, sulfate (1:1) |
| CHEBI:83314 |
| CHEMBL2107386 |
| D09766 |
| ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate sulfate |
| ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate sulfate |
| ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f]isobenzofuran-6-yl]carbamate; sulfuric acid |
| ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate;sulfuric acid |
| EX-A1149 |
| IN66038E6C |
| KB-80525 |
| MolPort-046-033-533 |
| N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester Sulfate |
| Sch 530348 |
| SCH 530348 H2SO4 Salt |
| SCH 530348 sulfate; Vorapaxar sulfate; MK5348 |
| SCH 530348|||MK-5348 |
| UNII-IN66038E6C |
| vorapaxar monosulfate |
| Vorapaxar sulfate (JAN/USAN) |
| Vorapaxar sulfate [USAN] |
| Zontivity (TN) |
US Patents and Regulatory Information for vorapaxar sulfate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Toprol | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Toprol | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Toprol | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Toprol | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for vorapaxar sulfate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1860106 | Start Trial |
| Peru | 02352002 | Start Trial |
| China | 101899039 | Start Trial |
| Brazil | PI0506761 | Start Trial |
| South Korea | 20030008161 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for vorapaxar sulfate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1495018 | CA 2015 00037 | Denmark | Start Trial | PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119 |
| 1495018 | 218 50011-2015 | Slovakia | Start Trial | PRODUCT NAME: VORAPAXARIUMSULFAT; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150121 |
| 1495018 | PA2015027 | Lithuania | Start Trial | PRODUCT NAME: VORAPAXARUM; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119 |
| 1495018 | PA2015027,C1495018 | Lithuania | Start Trial | PRODUCT NAME: VORAPAKSARAS; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119 |
| 1495018 | CR 2015 00037 | Denmark | Start Trial | PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.